Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis

Published Date:

04/28/2015

Source:

PubMed - NCBI

Authors:

Little KM, Pai M, Dowdy DW

External link

Original Article

There is growing concern that interferon-γ release assays (IGRAs) are being used off-label for the diagnosis of active tuberculosis (TB) disease in many high-burden settings, including India, where the background prevalence of latent TB infection is high. We analyzed the costs and consequences of using IGRAs for the diagnosis of active TB in India from the perspective of the Indian TB control sector.

Events

«

November 2018

»
S
M
T
W
T
F
S
·
·
·
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·

Projects

Understanding the costs and...

We have conducted an empirical costing analysis of facility-based versus community-based treatment for TB in Bangladesh and are...

Read More

Modeling the impact of spatially targeted TB...

 We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More

Quantiferon gold test for detecting TB...

This is a cluster randomized trial comparing the time to known latent TB status among HIV infected patients receiving QGIT...

Read More

ICOHRTA Training Program (Fogarty)

International Clinical, Operational, and Health Services Research Award (ICOHRTA) training program. A training program that...

Read More